InsiderTrades.com logo
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>

HFR Insider Trading

Insider Ownership Percentage: 22.99%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Highfield Resources Insider Trading History Chart

This chart shows the insider buying and selling history at Highfield Resources by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Highfield Resources Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for HFR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Strange new buyer driving up gold
From Stansberry Research   |   Ad
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
But there's a much better move you can make to get in front of these big moves today.

Highfield Resources Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/27/2023Ignacio SalazarInsiderExpiry1,472,878A$0.34A$500,778.52
8/11/2023Ignacio SalazarInsiderIssued2,639,296A$0.49A$1,280,058.56
6/30/2023Pauline CarrInsiderExpiry1,000,000A$0.55A$545,000.00
6/22/2022Paul HarrisInsiderIssued2,209,318A$0.73A$1,612,802.14
See Full Table
Strange new buyer driving up gold
From Stansberry Research   |   Ad
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
But there's a much better move you can make to get in front of these big moves today.

SEC Filings (Institutional Ownership Changes) for Highfield Resources (ASX:HFR)

29.18% of Highfield Resources stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Highfield Resources Limited, together with its subsidiaries, engages in the exploration and development of potash mines in Spain. The company's potash projects are located in the Ebro potash producing basin in Northern Spain. Its flagship property is the Muga project that targets shallow sylvinite beds in the Muga Project that covers an area of approximately 46 square kilometers located in the Provinces of Navarra and Aragón. The company also holds interest in the Pintanos tenement area comprising three permits of Molineras 1, Molineras 2, and Puntarrón covering an area of 65 square kilometers; and the Sierra del Perdón tenement area comprising three permits of Quiñones, Adiós, and Ampliación de Adiós coversing covering an area of approximately 120 square kilometers located to south east of Pamplona. The company was incorporated in 2011 and is headquartered in Pamplona, Spain.
Read More on Highfield Resources

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

36,238 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Who are the company insiders with the largest holdings of Highfield Resources?

Highfield Resources' top insider shareholders include:
  1. Ignacio Salazar (Insider)
  2. Paul Harris (Insider)
  3. Pauline Carr (Insider)
Learn More about top insider investors at Highfield Resources.
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>